Yes, Rexulti (brexpiprazole) is FDA-approved for the treatment of schizophrenia in adults and adolescents ages 13 years and older.
Rexulti is indicated as monotherapy for schizophrenia at a recommended dose of 2-4 mg once daily 1. This represents a clear, evidence-based treatment option supported by both regulatory approval and clinical trial data.
FDA-Approved Indications
Rexulti has three FDA-approved indications 1:
- Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
- Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults
- Treatment of agitation associated with dementia due to Alzheimer's disease
Clinical Evidence for Schizophrenia
The efficacy of brexpiprazole 2-4 mg/day has been demonstrated in multiple Phase 3 randomized controlled trials 2, 3. In acute schizophrenia exacerbations, brexpiprazole produced statistically significant improvements in PANSS (Positive and Negative Syndrome Scale) total scores compared to placebo, with treatment differences of -8.72 for the 2 mg dose and -7.64 for the 4 mg dose 3.
A recent 2026 meta-analysis confirmed these findings, showing brexpiprazole significantly improved:
- Total PANSS scores (mean difference -5.76; p < 0.00001) 4
- CGI-Severity scores (mean difference -1.35; p < 0.00001) 4
- Both positive and negative symptom subscales 4
Maintenance Treatment
For long-term maintenance, brexpiprazole demonstrated superior relapse prevention compared to placebo 2. In a 52-week maintenance study, significantly fewer patients relapsed on brexpiprazole versus placebo (13.5% vs. 38.5%), yielding a number needed to treat (NNT) of 4 5.
Positioning in Treatment Guidelines
While the most recent APA guidelines (2020) recommend antipsychotic treatment for schizophrenia broadly 6, they do not specifically endorse individual agents beyond clozapine for treatment-resistant cases. However, the 2025 Japanese Expert Consensus specifically identifies brexpiprazole as a first-line option for multiple clinical scenarios 7:
- First-line for positive symptoms (alongside risperidone, olanzapine, paliperidone, blonanserin)
- First-line for negative symptoms and cognitive impairment (alongside aripiprazole)
- First-line for patients at high risk of extrapyramidal side effects or diabetes mellitus
The 2025 INTEGRATE guidelines, while not specifically naming brexpiprazole, emphasize atypical antipsychotics as first-line agents 8, a category that includes brexpiprazole.
Safety and Tolerability Profile
Brexpiprazole demonstrates a favorable safety profile with relatively low rates of problematic side effects 9, 2:
Common Adverse Events
- Akathisia: Most common side effect (4.4-7.2% vs. 2.2% placebo in acute trials) 3, though the NNH is modest at 15 for MDD trials 5
- Weight gain: Moderate at approximately 1.28-1.45 kg over 6 weeks versus 0.42 kg for placebo 3
- Discontinuation due to adverse events: Lower than placebo in schizophrenia trials; NNH of 53 in MDD trials 5
Metabolic Effects
- Small, non-clinically significant changes in lipid and glucose levels 3
- Minimal effects on prolactin 5
- No clinically relevant QT interval prolongation 5
Extrapyramidal Symptoms
Brexpiprazole displays less intrinsic activity at D2 receptors than aripiprazole, predicting a lower propensity for activating adverse events and extrapyramidal symptoms 9. This is clinically relevant as the drug shows relatively low rates of sedation and activation 2.
Dosing and Administration
Start brexpiprazole at 1 mg once daily on Days 1-4, then increase to 2 mg on Days 5-7, with a target dose of 2-4 mg/day 1. The medication can be taken with or without food. Dose adjustments are required for:
- Strong/moderate CYP2D6 inhibitors
- Strong/moderate CYP3A4 inhibitors
- Poor CYP2D6 metabolizers
- Combination of moderate CYP2D6 and CYP3A4 inhibitors
Clinical Positioning
Brexpiprazole is best positioned as a first-line antipsychotic option, particularly for patients where tolerability concerns are paramount 10, 7. Its unique pharmacological profile as a partial D2 agonist with balanced serotonergic activity makes it suitable for:
First-episode schizophrenia: A 2026 post-hoc analysis demonstrated efficacy in early-episode patients (age 13-35, ≤5 years illness duration) with improvements in both PANSS scores and functioning measures 11
Patients requiring long-term maintenance: The favorable side effect profile facilitates adherence, which is critical given that 70% of patients require lifetime medication 12
Patients at risk for metabolic or extrapyramidal side effects: The drug's profile makes it preferable when these concerns exist 7
Important Caveats
Black Box Warning
Rexulti carries a black box warning for increased mortality risk in elderly patients with dementia-related psychosis 1. It is not approved for dementia-related psychosis without agitation.
Treatment-Resistant Schizophrenia
For patients who fail two adequate trials of antipsychotics (including at least one atypical agent), clozapine remains the gold standard 6. Brexpiprazole should not delay clozapine initiation in truly treatment-resistant cases.
Real-World Continuation
A 2026 Japanese inpatient study found 53.7% continuation at 8 weeks, with discontinuation most commonly due to adverse events (32.3%, primarily akathisia), insufficient efficacy (29%), and patient preference (22.6%) 13. This highlights the importance of monitoring and managing side effects early in treatment.